Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus

Virology

Volumn 280, Issue 2, 2001, Pages 211-220

  Kutinová, Lud'a ^a   Hainz, Petr ^a   Ludvíková, Viera ^a   Marešová, Lucie ^a   Němečková, Šárka ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Antibodies; Cellular imunity; Glycoproteins; Herpesviruses; Immunization; Vaccine; Vaccinia virus; Varicella zoster virus; Virus neutralization

Indexed keywords

COMPLEMENT; NEUTRALIZING ANTIBODY; PROTEIN GB; PROTEIN GE; PROTEIN GH; PROTEIN GL; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIG; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; SKIN TEST; VACCINIA VIRUS; VARICELLA ZOSTER VIRUS; VIRUS CULTURE; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; WESTERN BLOTTING;

CAVIA; HUMAN HERPESVIRUS 3; VACCINIA VIRUS;

EID: 0035866320     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0754     Document Type: Article

References (50)

1. A tyrosine-based motif and a casein kinase II phosphorylation site regulate the intracellular trafficking of the varicella-zoster virus glycoprotein I, a protein localized in the trans-Golgi network
2. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p. 170
3. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype
4. Antibodies to the three major glycoproteins of varicella-zoster virus: Search for the relevant host immune response
5. Western blot analysis of antibody to varicella-zoster virus
6. Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: Analysis by laser scanning confocal microscopy
7. Varicella-zoster virus envelope glycoproteins: Biochemical characterization and identification in clinical material
8. Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein
9. Antibody-induced endocytosis of viral glycoproteins and major histocompatibility complex class I on pseudorabies virus-infected monocytes
10. Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex
11. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects
12. In vitro enhancement of respiratory syncytial virus infection of U937 cells by human sera
13. Glycoproteins encoded by varicella-zoster virus: Biosynthesis, phosphorylation, and intracellular trafficking
14. Immunology of the varicella-zoster virus glycoproteins
15. Oligomeric structure of glycoproteins in herpes simplex virus type 1
16. Lipoproteins of varicella-zoster virus
17. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization
18. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals
19. Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones
20. A simple and sensitive assay for varicella-zoster virus
21. The varicella zoster virus glycoprotein B (gB) plays a role in virus binding to cell surface heparan sulfate proteoglycans
22. The purification of four strains of poxvirus
23. Diagnostic skin test reactions with varicella virus antigen and clinical application of the test
24. Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: Antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence
25. Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them
26. Hepatitis B virus proteins expressed by recombinant vaccinia viruses: Influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells
27. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62
28. Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant
29. Characterization of interaction of gH and gL glycoproteins of varicella-zoster virus, their processing and trafficking
30. Induction of neutralizing antibodies by varicella-zoster virus gpII glycoprotein expressed from recombinant vaccinia virus
31. Metabolism of cells in tissue culture in vitro. I. The influence of serum protein fractions on the growth of normal and neoplastic cells
32. Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII)
33. Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140)
34. Structural analysis of the varicella-zoster virus gp98-gp62 complex. Posttranslational addition of N-linked and O-linked oligosaccharide moieties
35. Evidence for attachment of fatty acid to varicella-zoster virus glycoproteins and effect of cerulenin on the maturation of varicella-zoster virus glycoproteins
36. Induction of varicella-zoster virus-neutralizing antibodies in mice by co-infection with recombinant vaccinia viruses expressing the gH or gL gene
37. Infection enhancement of influenza A H1 subtype viruses in macrophage-like P388D1 cells by cross-reactive antibodies
38. Endocytosis and recycling of varicella-zoster virus Fc receptor glycoprotein gE: Internalization mediated by a YXXL motif in the cytoplasmic tail
39. Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine
40. Virus particles and glycoprotein excreted from cultured cells infected with varicella-zoster virus (VZV)
41. Functions of purified gB, gE:gI, and gH:gL, and their sialyl residues in varicella-zoster virus infection
42. A human monoclonal antibody against varicella-zoster virus glycoprotein III
43. Antigenicity of a candidate varicella-zoster virus glycoprotein subunit vaccine
44. Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV
45. Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation
46. Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies
47. Varicella-zoster virus glycoprotein gpI/gpIV receptor: Expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system
48. Evaluation of varicella-zoster immune globulin: Protection of immunosuppressed children after household exposure to varicella
49. Targeting of glycoprotein I (gE) of varicella-zoster virus to the trans-Golgi network by an AYRV sequence and an acidic amino acid-rich patch in the cytosolic domain of the molecule